Universus Photo Imagings Ltd — FY26: A ₹395 Crore Market Cap, ₹19 Crore Revenue, and a Foreign Associate That Ate the Balance Sheet

General information and entertainment, not investment advice. The author is not a SEBI-registered adviser or research analyst. No recommendation, no promised returns. Markets carry risk including loss of capital. Figures may not be current. Consult a registered adviser before acting.

1 — At a Glance

Universus Photo Imagings Ltd (UPIL) closed FY26 with consolidated revenue of ₹18.78 crore and a consolidated net loss of ₹79.94 crore. The market cap sits at ₹395 crore — roughly 21x annual revenue, and roughly 0.50x book value.

The tension is architectural: on a standalone basis, the company earned a profit of ₹19.26 crore in FY26. Consolidated, it posted a loss of ₹79.94 crore. The gap is almost entirely explained by UPIL’s share of losses from its foreign associate, JPF Netherlands B.V. — ₹99.20 crore for the year. The associate’s audit for FY26 was not completed as of the date of these results, per the auditor’s report; figures have been consolidated on the basis of unaudited management-certified financials.

The standalone business — slitting and packaging X-Ray films at a Dadra facility — generated ₹18.78 crore in operating revenue. The company holds zero borrowings and a current ratio of 261. The book value per share stands at ₹741 against a market that prices the share at roughly half that.

A ₹395 crore market on ₹19 crore of revenue and a loss driven almost entirely by a foreign associate whose audit is still in progress: the numbers raise a question the article will return to.

2 — Introduction

Universus Photo Imagings Limited, formerly Jindal Photo Imaging Limited, was incorporated in 2011. Its registered office is at Bulandshahr, Uttar Pradesh; its corporate office operates from Vasant Kunj, New Delhi. The company is listed on both BSE (542933) and NSE (UNIVPHOTO).

The company’s structure has two layers. At the operating level, UPIL manufactures and packages X-Ray films and NTR films from its Dadra (UT-Dadra and Nagar Haveli) facility. At the holding level, it holds a stake in JPF Netherlands B.V., a foreign associate that contributes the majority of the consolidated balance sheet — and, in FY26, the majority of the consolidated loss.

Several events occurred during the year. In December 2025, the board approved subscribing to a rights issue in JPF Netherlands B.V. to acquire 39.87% at €3 per share, with expected completion in one to two months, per the announcement. UPIL gave ₹125.19 crore as subscription toward this rights issue during FY26, per Note 5 of the filing. In November 2025, the board approved Q2/H1 results showing a consolidated loss of ₹125.96 crore, with audit of the JPF associate still pending. In October 2025, the National Company Law Tribunal (NCLT), Allahabad, dismissed a shareholder oppression petition (C.P. 49/ALD/2022) on 15 October 2025, per the filing. In February 2024, shareholders approved a material related-party transaction with JPF Netherlands B.V.

The FY26 results were approved by the board on 29 May 2026. Statutory auditors M/s Suresh Kumar Mittal & Co. issued an unmodified opinion on both standalone and consolidated results, with an emphasis-of-matter paragraph flagging the unaudited associate figures.

3 — Business Model: WTF Do They Even Do?

UPIL’s operating business is, to put it plainly, a slitting operation. The company procures Jumbo Rolls of X-Ray film, slits them into prescribed sizes at its Dadra manufacturing unit, packages them, and sells. Installed capacity stands at approximately 3 lakh square metres per month — a figure that has not changed from FY20 to FY25, per the Screener insights table.

The product portfolio divides into two: X-Ray films (the medical imaging variety) and NTR films (No Transfer Ribbon films, used in photo albums, playing cards, gift cards, visiting cards, calendars, menu cards, wedding cards, and modelling portfolios). The NTR segment’s end-use list reads like a summary of analogue-era keepsakes, which rather neatly captures the company’s strategic position.

Management’s own filing acknowledges the risk: the business of X-Ray films is shrinking as digitisation advances. The Indian market for wet films, per management estimates in the Screener insights table, was 8 million square metres per annum around FY21 and had contracted to 1.75 million square metres by FY23. The company’s own revenue has declined from ₹62 crore in FY20 to ₹18.78 crore in FY26 — a five-year decline of roughly 70%.

Against this operating backdrop, the company has directed significant capital toward its foreign associate, JPF Netherlands B.V. The associate carries more than 20% of consolidated assets and profits/losses, per the auditor’s report. UPIL’s non-current investment in the associate stood at ₹544.36 crore as of March 2026 on the consolidated balance sheet.

The business model, in summary, has two moving parts that move in opposite directions: a domestic operation selling a declining product, and a foreign associate absorbing capital and generating consolidated losses.

Does the associate’s eventual audit resolution change the picture, or does it confirm it? The filing doesn’t say.

4 — Financials Overview

Figures are consolidated, in ₹ crore.

Annual P&L Summary

Latest Quarter (Q4 FY26 / Mar 2026)

The standalone Q4 PAT was ₹1.11 crore — a profit. The consolidated Q4 loss of ₹13.07 crore is almost entirely explained by the associate loss of ₹14.18 crore for the quarter, per the auditor’s other-matter paragraph.

The FY26 consolidated EPS of ₹(73.02) is the full-year figure. P/E is not calculable on negative earnings. The market’s pricing of the company is discussed in Section 5.

Notable filing item: As per Note 8 of the consolidated results, the impact of changes in FY25 figures — an increase in share of losses of ₹46.04 crore — was recognised in Other Equity in Q2 FY26, once the management-certified financials of JPF Netherlands for FY24-25 were available.

5 — Market Expectations & Historical Multiples

This section describes how the market is currently pricing